Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.57), $0.08 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $63.7 million versus the consensus estimate of $59.75 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.